Dialogues in Clinical Neuroscience
December 1, 2025
Ivona-Maria Tudorancea, Gabriela-Dumitrita Stanciu, Carla Torrent et al.
4 citations
The global population is ageing rapidly, with the number of individuals aged 60 and older reaching 1 billion in 2019 and expected to double by 2050. As people age, neuropsychological health often deteriorates, leading to a higher prevalence of age-related depression. Symptoms may include anxiety, apathy, mood instability, sadness, and, in severe cases, suicidal thoughts. Depression in the...
Dialogues in Clinical Neuroscience
December 1, 2025
Giulia Brizzi, Chiara Pupillo, Clara Rastelli et al.
Psychedelics were explored for their potential in the mental health field. However, research was delayed by concerns over short-term side effects and long-term consequences of substance use. Technological advances enabled the development of Hallucinatory Visual Virtual Experiences (HVVEs), namely psychedelic experiences simulations in immersive virtual reality. This study investigated HVVEs'...
Dialogues in Clinical Neuroscience
September 2, 2024
Shiven Chaudhry, Anne Weisman, Molly M. Hagen et al.
INTRODUCTION: This study evaluates the impact of a two-hour team-based learning (TBL) curriculum on medical students' knowledge, comprehension, ethical understanding, and attitudes towards psychedelic therapies. METHODS: Sixty-three pre-surveys and fifty post-surveys assessed students' perceived knowledge and attitudes using Likert scales. Forty-eight matched pre/post-knowledge tests with...
Dialogues in Clinical Neuroscience
May 20, 2024
Lionel Naccache, Esteban Munoz-Musat
Abstract We introduce here a general model of Functional Neurological Disorders based on the following hypothesis: a Functional Neurological Disorder could correspond to a consciously initiated voluntary top-down process causing involuntary lasting consequences that are consciously experienced and subjectively interpreted by the patient as involuntary. We develop this central hypothesis...
Dialogues in Clinical Neuroscience
June 30, 2019
David Nutt
131 citations
This article covers the renaissance of classical psychedelic drugs such as psilocybin and LSD plus 3,4-methylene dioxymethamphetamine (MDMA-ecstasy) in psychiatric research. These drugs were used quite extensively before they became prohibited. This ban had little impact on recreational use, but effectively stopped research and clinical treatments, which up to that point had looked very...
Dialogues in Clinical Neuroscience
March 31, 2014
Ronald S. Duman
248 citations
Despite the complexity and heterogeneity of mood disorders, basic and clinical research studies have begun to elucidate the pathophysiology of depression and to identify rapid, efficacious antidepressant agents. Stress and depression are associated with neuronal atrophy, characterized by loss of synaptic connections in key cortical and limbic brain regions implicated in depression. This is...
Dialogues in Clinical Neuroscience
March 1, 2012
Thomas Sturm
This paper is an overview of recent discussions concerning the mind-body problem, which is being addressed at the interface between philosophy and neuroscience. It focuses on phenomenal features of consciousness or "qualia," which are distinguished from various related issues. Then follows a discussion of various influential skeptical arguments that question the possibility of reductive...
Dialogues in Clinical Neuroscience
September 30, 2009
Euphrosyne Gouzoulis‐mayfrank, Jörg Daumann
115 citations
Ecstasy (MDMA, 3,4-methylendioxymethamphetamine) and the stimulants methamphetamine (METH, speed) and amphetamine are popular drugs among young people, particularly in the dance scene. When given in high doses both MDMA and the stimulant amphetamines are clearly neurotoxic in laboratory animals. MDMA causes selective and persistent lesions of central serotonergic nerve terminals, whereas...
Dialogues in Clinical Neuroscience
December 31, 2001
Franz X. Vollenweider
127 citations
This review focuses on recent brain imaging and behavioral studies of sensory gating functions, which assess similarities between the effects of classic hallucinogens (eg, psilocybin), dissociative anesthetics (eg, ketamine), and entactogens (eg, 3,4-methylenedioxymethamphetamine [MDMA]) in humans. Serotonergic hallucinogens and psychotomimetic anesthetics produce overlapping psychotic...